39668-87-6

Basic information

• Product Name: Cyclohexanecarbonyl chloride, 5-methyl-2-(1-methylethyl)- (9CI)
• Synonyms: Cyclohexanecarbonyl chloride, 5-methyl-2-(1-methylethyl)- (9CI);5-Methyl-2-(1-methylethyl)cyclohexanecarboxylic acid chloride
• CAS NO: 39668-87-6
• Molecular Formula: C₁₁H₁₉ClO
• Molecular Weight: 202.72096
• Product Categories: ACIDHALIDE
• Mol File: 39668-87-6.mol
• Article Data: 2

Chemical Properties

• Boiling Point: 240.7°Cat760mmHg
• Flash Point: 127.2°C
• Appearance: /
• Density: 0.99g/cm³
• Vapor Pressure: 0.0373mmHg at 25°C
• Refractive Index: 1.456
• CAS DataBase Reference: Cyclohexanecarbonyl chloride, 5-methyl-2-(1-methylethyl)- (9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanecarbonyl chloride, 5-methyl-2-(1-methylethyl)- (9CI)(39668-87-6)
• EPA Substance Registry System: Cyclohexanecarbonyl chloride, 5-methyl-2-(1-methylethyl)- (9CI)(39668-87-6)

Safety Data

• Hazardous Substances Data: 39668-87-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C11H19ClO/c1-7(2)9-5-4-8(3)6-10(9)11(12)13/h7-10H,4-6H2,1-3H3/t8-,9+,10-/m1/s1

Upstream product

• 39668-86-5 menthanecarboxylic acid 

Downstream Products

• 1254731-71-9 (1R,2S,5R)-2-isopropyl-5-methyl-N-(1-(pyridin-3-yl)propan-2-yl)cyclohexanecarboxamide 
• 68489-14-5 WS-5 
• 1207722-14-2 C₁₅H₂₇NO₃ 
• 91637-83-1 DL-Diazomethyl-menthyl-⁽³⁾-keton 
• 849705-47-1 N-(2'-methyl-4'-iodophenyl)-2-isopropyl-5-methylcyclohexanecarboxamide 
• 57233-20-2 2-(2'-hydroxyethoxy)-ethyl p-menthane-3-carboxylate 

Relevant articles and documents

Small-molecule modulators of TRP-P8 activity

Provided are small-molecule Trp-p8 modulators, including Trp-p8 agonists and Trp-p8 antagonists, and compositions comprising small-molecule Trp-p8 agonists as well as methods for identifying and characterizing novel small-molecule Trp-p8 modulators and methods for decreasing viability and/or inhibiting growth of Trp-p8 expressing cells, methods for activating Trp-p8-mediated cation influx, methods for stimulating apoptosis and/or necrosis, and related methods for the treatment of diseases, including cancers such as lung, breast, colon, and/or prostate cancers as well as other diseases, such as benign prostatic hyperplasia, that are associated with Trp-p8 expression.